Stock Analysis
Uniphar (ISE:UPR) Full Year 2023 Results
Key Financial Results
- Revenue: €2.55b (up 23% from FY 2022).
- Net income: €44.8m (down 1.7% from FY 2022).
- Profit margin: 1.8% (down from 2.2% in FY 2022). The decrease in margin was driven by higher expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Uniphar Revenues Beat Expectations
Revenue exceeded analyst estimates by 1.6%.
Looking ahead, revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Healthcare industry in Europe.
Performance of the market in Ireland.
The company's shares are down 7.2% from a week ago.
Valuation
It's possible that Uniphar could be undervalued with our 6-factor valuation analysis indicating a potential opportunity. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.
Valuation is complex, but we're helping make it simple.
Find out whether Uniphar is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ISE:UPR
Uniphar
Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally.
Undervalued with adequate balance sheet.